Home › Funds › BAKER BROS. ADVISORS LP › NGNE
BAKER BROS. ADVISORS LP position in NGNE
NEUROGENE INC COM · Health Care
BAKER BROS. ADVISORS LP reported holding 991,691 shares of NGNE (NEUROGENE INC COM) in its Q2 2026 13F filing — a position valued at US$31.2M, representing 0.16% of its reported portfolio and ranking #45 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's NGNE position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in NGNE in Q4 2023 at 453,516 shares (US$8.8M). The position peaked in Q2 2026 at 991,691 shares, worth US$31.2M. Across 11 filings, BAKER BROS. ADVISORS LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 991,691 shares valued at US$31.2M. Notable position changes include a 48% increase in Q4 2024 (shares fell 49% over the following quarter), a 120% increase in Q1 2025 (shares rose 28% over the following quarter), a 33% trim in Q2 2025 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 453.52K | $8.79M | New |
| Q1 2024 | 456.01K | $23.21M | Add |
| Q2 2024 | 456.01K | $16.59M | Hold |
| Q3 2024 | 456.01K | $19.13M | Hold |
| Q4 2024 | 674.45K | $15.42M | Add |
| Q1 2025 | 1.49M | $17.40M | Add |
| Q2 2025 | 991.69K | $14.83M | Reduce |
| Q3 2025 | 991.69K | $17.19M | Hold |
| Q4 2025 | 991.69K | $20.43M | Hold |
| Q1 2026 | 991.69K | $19.99M | Hold |
| Q2 2026 | 991.69K | $31.19M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NGNE and 13F data
NGNE (NEUROGENE INC COM) is a Health Care company. 37 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$54.0M), Casdin Capital (US$48.6M), Redmile Group, LLC (US$44.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.72M sh · $54.00M · Q2 2026
- Casdin Capital 1.55M sh · $48.60M · Q2 2026
- Redmile Group, LLC 1.41M sh · $44.41M · Q2 2026
- RTW INVESTMENTS, LP 1.36M sh · $42.85M · Q2 2026
- EcoR1 Capital, LLC 1.27M sh · $39.98M · Q2 2026
- Trails Edge Capital Partners, LP 714.88K sh · $22.48M · Q2 2026
- GREAT POINT PARTNERS LLC 352.18K sh · $11.08M · Q2 2026
- DAFNA Capital Management LLC 89.03K sh · $2.80M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held NGNE?
BAKER BROS. ADVISORS LP has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is BAKER BROS. ADVISORS LP's current position in NGNE?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 991.69K shares of NGNE (NEUROGENE INC COM), valued at $31.19M, representing 0.16% of its reported portfolio and ranking #45.
Has BAKER BROS. ADVISORS LP been buying or selling NGNE?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in NGNE. The position peaked in Q2 2026 at 991.69K shares.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, Redmile Group, LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.